Laura Guay
Laura Guay
M.D.
Research Professor
School: Milken Institute School of Public Health
Department: Epidemiology
Contact:
Email:
Laura Guay
Laura A. Guay is Research Professor in the Department of Epidemiology and Biostatistics.
Africa has long had a draw for Dr. Laura Guay. Her 20-year career, devoted to the challenge of curbing HIV infection in women and children on the continent, began with a GWU medical school elective in the former Zaire, followed by a three-year HIV research project as a visiting lecturer at Makerere University in Kampala, Uganda after her pediatric residency. Dr. Guay returned to Uganda after her ID fellowship and worked on the landmark HIVNET 012 trial, which demonstrated that a single-dose of the antiviral medication nevirapine to a mother and her infant could prevent mother-to-child HIV transmission. Dr. Guay joined the GW SPH faculty in 2008, at the same time she became Vice President for Research at the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). As part of a broader effort to strengthen ties between the two organizations, she mentors graduate students conducting research and completing practicums at EGPAF and lectures as an invited guest in Department of Epidemiology and Biostatistics courses. Dr. Guay remains on the faculty of the Johns Hopkins University School of Medicine, where she has been since 1996. She was the principal investigator of a multi-million dollar grant from the National Institute of Health's Division of AIDS, which supports the Uganda clinical trials unit collaboratively operated by Makerere and Johns Hopkins.
HIV/AIDS
Prevention
Bachelor of Arts (Biology/French), University of Rochester, 1981
Doctor of Medicine, George Washington University, 1985
Fellowship, Pediatric Infectious Diseases, Case Western Reserve University, 1994
Dr. Guay is a member of the Office of the Global AIDS Coordinator's Expert Panel on the Prevention of Mother-to-Child HIV transmission, a State Department entity that makes recommendations for scaling up prevention services. She is also a member of the WHO guideline committee, which is reviewing guidelines for treating pregnant women and preventing HIV transmission to their infants, and of the Pediatric HIV Vaccine Data Monitoring Ethics Committee, which is monitoring HIV vaccine trials in Kenya and the Gambia.
Dr. Guay's current research interests focus on HIV in women and children, particularly preventing transmission through breastfeeding. She also serves as the technical lead on an SPHHS/UNICEF collaborative project that is analyzing implementation research on preventing mother-to-child HIV transmission and on pediatric HIV care.
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial Coovadia, Hoosen M (12/2011). "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial". The Lancet (British edition) (0140-6736)
Safety and Efficacy of HIV Hyperimmune Globulin for Prevention of Mother-to-Child HIV Transmission in HIV-1:Infected Pregnant Women and Their Infants in Kampala, Uganda (HIVIGLOB/NVP STUDY) Onyango-Makumbi, Carolyne (12/2011). "Safety and Efficacy of HIV Hyperimmune Globulin for Prevention of Mother-to-Child HIV Transmission in HIV-1:Infected Pregnant Women and Their Infants in Kampala, Uganda (HIVIGLOB/NVP STUDY)". Journal of acquired immune deficiency syndromes (1999) (1525-4135), 58 (4), 399.
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda Mmiro FA, Aizire J, Mwatha AK, Eshleman SH, Donnell D, Fowler MG, Nakabiito C, Musoke PM, Jackson JB, Guay LA. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):32-9. PMCID: PMC2767188.
Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, UgandaOnyango-Makumbi C, Bagenda D, Mwatha A, Omer SB, Musoke P, Mmiro F, Zwerski SL, Kateera BA, Musisi M, Fowler MG, Jackson JB, Guay LA. Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, Uganda. J Acquir Immune Defic Syndr. 2009 Sep 25. [Epub ahead of print]
Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation Taube JM, Kamira B, Motevalli M, Nakabiito C, Lukande R, Kelly DP, Erozan YS, Gravitt PE, Buresh ME, Mmiro F, Bagenda D, Guay LA, Jackson JB. Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation. Diagn Cytopathol. 2009 Nov 24.[Epub ahead of print]
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. Singh KK, Hughes MD, Chen J, et al. "Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals." J Acquir Immune Defic Syndr 2008 Nov 1;49 (3):259-65.
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6b weeks of age to prevent HIV vertical transmission Church JD. Omer SB, Guay LA, et al. "Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6b weeks of age to prevent HIV vertical transmission." J Infect Dis 2008 Oct 1;198 (7):1075-82.
Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children Musoke PM, Young AM, Owor MA, et al. "Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children." J Acquir Immune Defic Syndr 2008 Oct 1;49 (2):171-8.
Analysis of nevirapine resistance mutations in cloned HIV-1 variants from HIV-infected Ugandan infants using a single step amplification-sequencing method (AmpliSeq) Towler WI, Church JD, Eshleman JR, et al. "Analysis of nevirapine resistance mutations in cloned HIV-1 variants from HIV-infected Ugandan infants using a single step amplification-sequencing method (AmpliSeq)." AIDS Res Hum Retroviruses 2008 Sep;24 (9):1209-13.
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials. Six Week Extended-Dose Nevirapine (SWEN) Team. "Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials." Lancet 2008 Jul 26;372 (9635):300-13.
HIV-1 tropism and survival in vertically infected Ugandan infants. Church JD, Huang W, Mwatha A, et al. "HIV-1 tropism and survival in vertically infected Ugandan infants." J Infect Dis 2008;197 (10):1382-88.
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine Flys T, Mwatha A, Guay LA, et al. "Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine." AIDS 2007;21:2077-82.
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. Church JD, Hudelson SE, Guay LA, et al. "HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D." AIDS Res Hum Retroviruses 2007;23 (6):764-8.